644
Participants
Start Date
November 25, 2020
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
SOC plus 15mg/kg EB05 IV
Standard of care plus single IV infusion of 15mg/kg of EB05.
SOC plus Placebo IV
Standard of care plus a single IV infusion of placebo.
University of Miami Hospital, Coral Gables
Wayne State University, Detroit
St. Jude Medical Center/ Providence, Fullerton
UCSF Fresno, Fresno
Providence Portland Medical Center, Portland
Baystate Medical Center, Springfield
West Virginia University Medicine Heart & Vascular Institute, Morgantown
University of Alberta Hospital, Edmonton
Vancouver Coastal Health, Vancouver
Vancouver General Hospital, Vancouver
William Osler Health System, Brampton
Markham Stouffville Hospital, Markham
Southlake Regional Health Centre, Newmarket
Lakeridge Health, Oshawa
Ottawa Hospital Research Institute, Ottawa
Toronto General Hospital, Toronto
CISS Monteregie-Centre, Greenfield Park
Hôpital Maisonneuve Rosemont, Montreal
McGill University Health Centre, Montreal
Hôpital Régional de Rimouski, Rimouski
Lead Sponsor
Collaborators (1)
JSS Medical Research Inc.
INDUSTRY
Edesa Biotech Inc.
INDUSTRY